Forced degradation studies: an essential tool for the formulation development of vaccines

References

• Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895–913.
   PubMed Web of Science ®Google Scholar
• Kats M.[webpage on Internet]. Forced Degradation Studies: Regulatory Considerations and Implementation; 2005. Available from: http://www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=170505.
   Google Scholar
• International Conference on Harmonization. Q1B: Photostability Testing of New Drug Substances and Products. US Department of Health and Human Services; Rockville, MD: 1997;62(95):27115–27122.
   Google Scholar
• International Conference on Harmonization. Q2(R1): Validation of Analytical Procedures: Text and Methodology. London, UK: European Medicines Agency; 1995;60(11260):27463–27467.
   Google Scholar
• International Conference on Harmonization. Q3A(R2): Impurities in New Drug Substances. Published in the Federal Register on Jun 2008.
   Google Scholar
• International Conference on Harmonization. Q3B(R2): Impurities in New Drug Products. London, UK: European Medicines Agency; 2003;68(220):64628–64629.
   Google Scholar
• International Conference on Harmonization. Q5C: Stability Testing of Biotechnological/Biological Products. London, UK: European Medicines Agency; 1996;61:36466.
   Google Scholar
• International Conference on Harmonization. ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process. Silver Spring, MD: Food and Drug Administration; 2005;70(125):37861–37862.
   Google Scholar
• International Conference on Harmonization. Q6B: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. London, UK: European Medicines Agency; 1999;64:44928.
   Google Scholar
• International Conference on Harmonization. Q8(R2): Pharmaceutical Development. Published in the Federal Register, Nov 2009, Vol. 71.
   Google Scholar
• International Conference on Harmonization. Q11: Development and Manufacture of Drug Substances. Silver Spring, MD: US Department of Health and Human Services; 2012;77(224):69634–69635.
   Google Scholar
• Bee JS, Chiu D, Sawicki S, et al. Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. JPharm Sci. 2009;98(9):3218–3238.
   PubMed Web of Science ®Google Scholar
• Bhatt NP, Patel K, Borchardt RT. Chemical pathways of peptide degradation. I. Deamidation of adrenocorticotropic hormone. Pharm Res. 1990;7(6):593–599.
   PubMed Web of Science ®Google Scholar
• Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res. 2003;20(9):1325–1336.
   PubMed Web of Science ®Google Scholar
• Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575.
   PubMed Web of Science ®Google Scholar
• Yan B, Steen S, Hambly D, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci. 2009;98(10):3509–3521.
   PubMed Web of Science ®Google Scholar
• Wingfield PT, Mattaliano RJ, MacDonald HR, et al. Recombinant- derived interleukin-1 alpha stabilized against specific deamidation. Protein Eng. 1987;1(5):413–417.
   Google Scholar
• Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity. 2007;40(2):131–137.
   PubMed Web of Science ®Google Scholar
• Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol. 2008;39(2):113–118.
   PubMed Web of Science ®Google Scholar
• Oliyai C, Patel JP, Carr L, Borchardt RT. Chemical pathways of peptide degradation. VII. Solid state chemical instability of an aspartyl residue in a model hexapeptide. Pharm Res. 1994;11(6):901–908.
   Web of Science ®Google Scholar
• Patel K, Borchardt RT. Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of aspar- aginyl residues in hexapeptides. Pharm Res. 1990;7(8):787–793.
   Web of Science ®Google Scholar
• Wakankar AA, Borchardt RT. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci. 2006;95(11):2321–2336.
   PubMed Web of Science ®Google Scholar
• Hem SL, HogenEsch H, Middaugh CR, Volkin DB. Preformulation studies - The next advance in aluminum adjuvant-containing vaccines. Vaccine. 2010;28(31):4868–4870.
   PubMed Web of Science ®Google Scholar
• Clarke S, Stephenson RC, Lowenson JD. Lability of asparagine and aspartic acid residues in proteins and peptides: spontaneous deamidation and isomerization reactions. In Ahern T, Manning MC, editors. Stability of Protein Pharmaceuticals Part A: Chemical and Physical Pathways of Protein Degradation. New York, NY: Plenum Press; 1992:1–29.
   Google Scholar
• Powell BS, Enama JT, Ribot WJ, et al. Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity. Proteins. 2007;68(2):458–479.
   PubMed Web of Science ®Google Scholar
• Estey T, Vessely C, Randolph TW, et al. Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. J Pharm Sci. 2009;98(9):2994–3012.
   Web of Science ®Google Scholar
• Volkin DB, Mach H, Middaugh CR. Degradative covalent reactions important to protein stability. Mol Biotechnol. 1997;8(2):105–122.
   Web of Science ®Google Scholar
• George-Nascimento C, Lowenson J, Borissenko M, et al. Replacement of a labile aspartyl residue increases the stability of human epidermal growth factor. Biochemistry. 1990;29(41):9584–9591.
   Web of Science ®Google Scholar
• Liu WR, Langer R, Klibanov AM. Moisture-induced aggregation of lyophilized proteins in the solid state. Biotechnol Bioeng. 1991;37(2):177–184.
   Web of Science ®Google Scholar
• Zhao Q, Wang Y, Abraham D, Towne V, Kennedy R, Sitrin RD. Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. Biochem Biophys Res Commun. 2011;408(3):447–453.
   PubMed Web of Science ®Google Scholar
• Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6(11):903–918.
   PubMed Web of Science ®Google Scholar
• Pogocki D, Ghezzo-Schöneich E, Schöneich C. Conformational flexibility controls proton transfer between the methionine hydroxy sulfuranyl radical and the N-terminal amino group in Thr-(X)n-Met peptides. J Phys Chem B. 2001;105(6):1250–1259.
   Web of Science ®Google Scholar
• Haensler J. Liposomal adjuvants: preparation and formulation with antigens. Methods Mol Biol. 2010;626:73–90.
   PubMedGoogle Scholar
• Amanna IJ, Raue HP, Slifka MK. Development of a new hydrogen peroxide-based vaccine platform. Nat Med. 2012;18(6):974–979.
   PubMed Web of Science ®Google Scholar
• Reis A, Spickett CM. Chemistry of phospholipid oxidation. Biochim Biophys Acta. 2012;1818(10):2374–2387.
   PubMed Web of Science ®Google Scholar
• Jurkiewicz P, Olzynska A, Cwiklik L, et al. Biophysics of lipid bilayers containing oxidatively modified phospholipids: Insights from fluorescence and EPR experiments and from MD simulations. Biochim Biophys Acta. 2012;1818(10):2388–2402.
   PubMed Web of Science ®Google Scholar
• Mosca M, Ceglie A, Ambrosone L. Effect of membrane composition on lipid oxidation in liposomes. Chem Phys Lipids. 2011;164(2):158–165.
   PubMed Web of Science ®Google Scholar
• Reis A, Domingues MR, Amado FM, Ferrer-Correia AJ, Domingues P. Separation of peroxidation products of diacyl-phosphatidylcholines by reversed-phase liquid chromatography-mass spectrometry. Biomed Chromatogr. 2005;19(2):129–137.
   PubMed Web of Science ®Google Scholar
• Demple B, Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem. 1994;63:915–948.
   PubMed Web of Science ®Google Scholar
• Middaugh CR, Evans RK, Montgomery DL, Casimiro DR. Analysis of plasmid DNA from a pharmaceutical perspective. J Pharm Sci. 1998;87(2):130–146.
   PubMed Web of Science ®Google Scholar
• Chen D, Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev Vaccines. 2009;8(5):547–557.
   PubMed Web of Science ®Google Scholar
• Frasch CE. Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges. Vaccine. 2009;27(46):6468–6470.
   PubMed Web of Science ®Google Scholar
• Sturgess AW, Rush K, Charbonneau RJ, et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine. 1999;17(9–10):1169–1178.
   PubMed Web of Science ®Google Scholar
• Putz MM, Ammerlaan W, Schneider F, Jung G, Muller CP. Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens. Vaccine. 2004;22(31–32):4173–4182.
   Web of Science ®Google Scholar
• Philo JS, Arakawa T. Mechanisms of protein aggregation. Curr Pharm Biotechnol. 2009;10(4):348–351.
   PubMed Web of Science ®Google Scholar
• Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98(9):2909–2934.
   PubMed Web of Science ®Google Scholar
• Hutchings RL, M Singh S, Cabello-Villegas J, Mallela KM. Effect of antimicrobial preservatives on partial protein unfolding and aggregation. J Pharm Sci. 2013;102(2):365–376.
   Web of Science ®Google Scholar
• Majumdar S, Ford BM, Mar KD, Sullivan VJ, Ulrich RG, D’Souza AJ. Evaluation of the effect of syringe surfaces on protein formulations. J Pharm Sci. 2011;100(7):2563–2573.
   Web of Science ®Google Scholar
• Singh SK, Afonina N, Awwad M, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci. 2010;99(8):3302–3321.
   Web of Science ®Google Scholar
• Clapp T, Siebert P, Chen D, Jones Braun L. Vaccines with aluminum- containing adjuvants: optimizing vaccine efficacy and thermal stability. J Pharm Sci. 2011;100(2):388–401.
   PubMed Web of Science ®Google Scholar
• Bolgiano B, Mawas F, Yost SE, Crane DT, Lemercinier X, Corbel MJ. Effect of physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM(197) conjugate vaccines. Vaccine. 2001;19(23—24):3189–3200.
   Web of Science ®Google Scholar
• Ratliff TL, Ritchey JK, Brandhorst J, Hanna MG Jr. Time-dependent aggregation of reconstituted BCG vaccine. J Urol. 1994;152(6 Pt 1):2147–2150.
   Web of Science ®Google Scholar
• Warren HS, Vogel FR, Chedid LA. Current status of immunological adjuvants. Annu Rev Immunol. 1986;4:369–388.
   PubMed Web of Science ®Google Scholar
• Salnikova MS, Davis H, Mensch C, Celano L, Thiriot DS. Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants. J Pharm Sci. 2012;101(3):1050–1062.
   Web of Science ®Google Scholar
• Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of vaccines. J Pharm Sci. 2003;92(2):218–231.
   PubMed Web of Science ®Google Scholar
• Cai S, He F, Samra HS, et al. Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Mol Pharm. 2009;6(5):1553–1561.
   Google Scholar
• Hu L, Joshi SB, Liyanage MR, et al. Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine. J Pharm Sci. 2013;102(2):387–400.
   PubMed Web of Science ®Google Scholar
• Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J Biol Chem. 2006;281(28):19478–19488.
   PubMed Web of Science ®Google Scholar
• Kissmann J, Ausar SF, Foubert TR, et al. Physical stabilization of Norwalk virus-like particles. J Pharm Sci. 2008;97(10):4208–4218.
   PubMed Web of Science ®Google Scholar
• Ausar SF, Rexroad J, Frolov VG, Look JL, Konar N, Middaugh CR. Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol Pharm. 2005;2(6):491–499.
   Google Scholar
• Kissmann J, Ausar SF, Rudolph A, et al. Stabilization of measles virus for vaccine formulation. Hum Vaccin. 2008;4(5):350–359.
   PubMed Web of Science ®Google Scholar
• Ausar SF, Espina M, Brock J, et al. High-throughput screening of stabilizers for respiratory syncytial virus: identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum Vaccin. 2007;3(3):94–103.
   PubMed Web of Science ®Google Scholar
• Volkin DB, Burke CJ, Marfia KE, Oswald CB, Wolanski B, Middaugh CR. Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine. J Pharm Sci. 1997;86(6):666–673.
   Web of Science ®Google Scholar
• Burke CJ, Hsu TA, Volkin DB. Formulation, stability, and delivery of live attenuated vaccines for human use. Crit Rev Ther Drug Carrier Syst. 1999;16(1):1–83.
   Web of Science ®Google Scholar
• Ausar SF, Joshi SB, Middaugh CR. Spectroscopic methods for the physical characterization and formulation of nonviral gene delivery systems. Methods Mol Biol. 2008;434:55–80.
   Google Scholar
• Chen V, Kim KJ, Fane AG. Effect of membrane morphology and operation on protein deposition in ultrafiltration membranes. Biotechnol Bioeng. 1995;47(2):174–180.
   Web of Science ®Google Scholar
• Kee GS, Pujar NS, Titchener-Hooker NJ. Study of detergent-mediated liberation of hepatitis B virus-like particles from S. cerevisiae homogenate: identifying a framework for the design of future-generation lipoprotein vaccine processes. Biotechnol Prog. 2008;24(3):623–631.
   Web of Science ®Google Scholar
• Kim KJ, Chen V, Fane AG. Some factors determining protein aggregation during ultrafiltration. Biotechnol Bioeng. 1993;42(2):260–265.
   PubMed Web of Science ®Google Scholar
• Russell WM, Burch RL. Prefatory Note. Altern Lab Anim. 2009;37(3):267–268.
   Web of Science ®Google Scholar
• Habig WH. Potency testing of bacterial vaccines for human use. Vet Microbiol. 1993;37(3–4):343–351.
   Web of Science ®Google Scholar
• Festing MF. Reduction in animal use in the production and testing of biologicals. Dev Biol Stand. 1999;101:195–200.
   Google Scholar
• Ljutic B, Ochs M, Messham B, et al. Formulation, stability and immu- nogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. Vaccine. 2012;30(19):2981–2988.
   Web of Science ®Google Scholar
• Krell T, Manin C, Nicolai MC, et al. Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry. BiotechnolApplBiochem. 2005;41(Pt 3):241–246.
   Google Scholar
• Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem. 2005;280(14):13406–13414.
   PubMed Web of Science ®Google Scholar
• Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci. Epub June 6, 2011.
   Google Scholar
• Metz B, Hendriksen CF, Jiskoot W, Kersten GF. Reduction of animal use in human vaccine quality control: opportunities and problems. Vaccine. 2002;20(19–20):2411–2430.
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Johnson KL, Naylor S. The role of mass spectrometry in vaccine development. Vaccine. 2001;19(17–19):2692–2700.
   Web of Science ®Google Scholar
• Metz B, Brunel F, Chamberlin C, et al. The potential of physicochemical and immunochemical assays to replace animal tests in the quality control of toxoid vaccines. The report and recommendations of ECVAM workshop 61. Altern Lab Anim. 2007;35(3):323–331.
   Web of Science ®Google Scholar
• Xing DK, Crane DT, Bolgiano B, Corbel MJ, Jones C, Sesardic D. Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro. Vaccine. 1996;14(13):1205–1213.
   PubMed Web of Science ®Google Scholar
• Ausar SF, Chan J, Hoque W, James O, Jayasundara K, Harper K. Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines. J Pharm Sci. 2011;100(2):431–440.
   PubMed Web of Science ®Google Scholar
• Costantino HR, Schwendeman SP, Griebenow K, Klibanov AM, Langer R. The secondary structure and aggregation of lyophilized tetanus toxoid. J Pharm Sci. 1996;85(12):1290–1293.
   Web of Science ®Google Scholar
• Carra JH, Wannemacher RW, Tammariello RF, et al. Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. Vaccine. 2007;25(21):4149–4158.
   PubMed Web of Science ®Google Scholar
• Sweeney JA, Sumner JS, Hennessey JP Jr. Simultaneous evaluation of molecular size and antigenic stability of PNEUMOVAX 23, a multivalent pneumococcal polysaccharide vaccine. Dev Biol (Basel). 2000;103:11–26.
   Google Scholar
• Hutcheon CJ, Becker JO, Russell BA, Bariola PA, Peterson GJ, Stroop SD. Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant. Vaccine. 2006;24(49—50):7214–7225.
   Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501—E507.
   Web of Science ®Google Scholar
• EMEA. Production and Quality Control of Monoclonal Antibodies and Related Substances. [EMEA/CHMP/BWP/15763/2007]. 2007.
   Google Scholar
• Wilson GA, Manning MC. Flow imaging: moving toward best practices for subvisible particle quantitation in protein products. J Pharm Sci. 2013;102(3):1133–1134.
   Web of Science ®Google Scholar
• Plieskatt JL, Rezende WC, Olsen CM, et al. Advances in vaccines against neglected tropical diseases: enhancing physical stability of a recombinant hookworm vaccine through biophysical and formulation studies. Hum Vaccin Immunother. 2012;8(6):765–776.
   Web of Science ®Google Scholar
• Kolhe P, Badkar A. Protein and solute distribution in drug substance containers during frozen storage and post-thawing: a tool to understand and define freezing-thawing parameters in biotechnology process development. Biotechnol Prog. 2011;27(2):494–504.
   PubMed Web of Science ®Google Scholar
• Chang BS, Kendrick BS, Carpenter JF. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci. 1996;85(12):1325–1330.
   PubMed Web of Science ®Google Scholar
• Treuheit MJ, Kosky AA, Brems DN. Inverse relationship of protein concentration and aggregation. Pharm Res. 2002;19(4):511–516.
   PubMed Web of Science ®Google Scholar
• Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505–523.
   PubMed Web of Science ®Google Scholar
• Maa YF, Hsu CC. Effect of high shear on proteins. Biotechnol Bioeng. 1996;51(4):458–465.
   PubMed Web of Science ®Google Scholar
• Eppler A, Weigandt M, Hanefeld A, Bunjes H. Relevant shaking stress conditions for antibody preformulation development. Eur J Pharm Biopharm. 2010;74(2):139–147.
   Web of Science ®Google Scholar
• Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. JPharm Sci. 2007;96(6):1468–1479.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonization. Q1A(R2): Stability Testing of New Drug Substances and Products. Rockville, MD: US Department of Health and Human Services; 2003.
   Google Scholar
• Volkin DB, Burke CJ, Sanyal G, Middaugh CR. Analysis of vaccine stability. Dev Biol Stand. 1996;87:135–142.
   Google Scholar
• Melnick JL, Wallis C. Effect of pH on thermal stabilization of oral poliovirus vaccine by magnesium chloride. Proc Soc Exp Biol Med. 1963;112:894–897.
   Web of Science ®Google Scholar
• Bam NB, Cleland JL, Yang J, et al. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci. 1998;87(12):1554–1559.
   PubMed Web of Science ®Google Scholar
• Lina B, Fletcher MA, Valette M, Saliou P, Aymard M. A TritonX- 100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly. Biologicals. 2000;28(2):95–103.
   PubMed Web of Science ®Google Scholar
• Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev. 2011;63(13):1118–1159.
   PubMed Web of Science ®Google Scholar
• Shukla D, Trout BL. Understanding the synergistic effect of arginine and glutamic acid mixtures on protein solubility. J Phys Chem B. 2011;115(41):11831–11839.
   Web of Science ®Google Scholar
• Markus HZ, McAleer WJ, inventors; Merck & Co, applicant. Vaccine stabilizer containing L-glutamic acid and L-arginine. United States patent US 4337242A. May 19, 1982.
   Google Scholar
• Timasheff SN. Protein-solvent preferential interactions, protein hydration, and the modulation of biochemical reactions by solvent components. Proc Natl Acad Sci U S A. 2002;99(15):9721–9726.
   PubMed Web of Science ®Google Scholar
• Ricker JV, Tsvetkova NM, Wolkers WF, et al. Trehalose maintains phase separation in an air-dried binary lipid mixture. Biophys J. 2003;84(5):3045–3051.
   Web of Science ®Google Scholar
• Thyagarajapuram N, Olsen D, Middaugh CR. Stabilization ofproteins by recombinant human gelatins. J Pharm Sci. 2007;96(12):3304–3315.
   Web of Science ®Google Scholar
• Evans RK, Nawrocki DK, Isopi LA, et al. Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci. 2004;93(10):2458–2475
   PubMed Web of Science ®Google Scholar